Wild Bioscience, an Oxford University AgTech spinout that develops improved crop varieties using AI and precision breeding, has raised a €51 million Series A investment to expand their R&D and commercial operations, and to turn their early field successes into market-ready seed varieties.
This round was led by the Ellison Institute of Technology (EIT), with participation from existing investors Oxford Science Enterprises (OSE), Braavos Capital, and the Oxford University.
Dr Ross Hendron, Co-Founder and CEO of Wild Bio says: "Advancing agriculture has limitless potential to help people and the planet. So to achieve meaningful, scalable impact, we need the right investors who are truly aligned with that big vision. I'm deeply grateful to EIT and to our current investors for sharing our excitement about what we've accomplished so far, and for their united support as we embark on this ambitious growth journey together."
Wild Bioscience's Series A positions it among the most substantial early-stage financings in European AgriTech this year. Most peer investments in 2025 have ranged between €2 million and €10 million, typically focused on AI analytics, robotics, or data-driven farming tools rather than genetics or breeding.
Read more at EU Startups
